InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
Globe Newswire (Fri, 8-May 8:15 AM ET)
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
Globe Newswire (Wed, 6-May 8:30 AM ET)
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
Globe Newswire (Wed, 6-May 8:25 AM ET)
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
Globe Newswire (Mon, 4-May 7:30 AM ET)
InflaRx to Report First Quarter 2026 Results on May 7, 2026
Globe Newswire (Fri, 1-May 7:30 AM ET)
InflaRx Regains Nasdaq Compliance After 10-Day Bid Price Streak
Market Chameleon (Tue, 28-Apr 6:31 AM ET)
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Tue, 28-Apr 7:30 AM ET)
Globe Newswire (Thu, 9-Apr 7:30 AM ET)
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
Globe Newswire (Tue, 31-Mar 7:30 AM ET)
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Inflarx N.V. trades on the NASDAQ stock market under the symbol IFRX.
As of June 15, 2026, IFRX stock price declined to $1.55 with 276,416 million shares trading.
IFRX has a beta of 3.13, meaning it tends to be more sensitive to market movements. IFRX has a correlation of 0.12 to the broad based SPY ETF.
IFRX has a market cap of $228.30 million. This is considered a Small Cap stock.
Last quarter Inflarx N.V. reported $0 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-10,000 and exceeded earnings estimates by $.08.
In the last 3 years, IFRX traded as high as $4.70 and as low as $.71.
IFRX has outperformed the market in the last year with a return of +93.7%, while the SPY ETF gained +26.5%. In the last 3 month period, IFRX beat the market returning +58.0%, while SPY returned +13.8%. However, in the most recent 2 weeks IFRX has underperformed the stock market by returning -35.4%, while SPY returned 0.0%.
IFRX support price is $1.52 and resistance is $1.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IFRX shares will trade within this expected range on the day.